Alpha Tau MedicalDRTS -5.56%28 Return-on-Tangible-Asset is -85.58% as of Mar. 2026. GuruFocus rates DRTS with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Alpha Tau Medical ranks worse than 63.17% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Alpha Tau Medical's annualizedNet Income for the quarter that ended in Mar. 2026 was $-91.76 Mil. Alpha Tau Medical's average total tangible assets for the quarter that ended in Mar. 2026 was $107.21 Mil. Therefore, Alpha Tau Medical's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -85.58%.
The historical rank and industry rank for Alpha Tau Medical's Return-on-Tangible-Asset or its related term are showing as below:
DRTS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -57.29 Med: -32.8 Max: -21.01
Current: -55.65
During the past 7 years, Alpha Tau Medical's highest Return-on-Tangible-Asset was -21.01%. The lowest was -57.29%. And the median was -32.80%.
DRTS's Return-on-Tangible-Asset is ranked worse than 63.17% of 1412
companies
in the Biotechnology industry
Industry Median: -35.66
vs DRTS: -55.65
Alpha Tau Medical (NAS:DRTS) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Alpha Tau Medical Return-on-Tangible-Asset Related Terms
Alpha Tau Medical Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Alpha Tau Medical's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DRTS vs ORIC, OLMA, KURA: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Alpha Tau Medical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -85.58% mean?
Alpha Tau Medical (DRTS) has a Return-on-Tangible-Asset of -85.58% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Alpha Tau Medical and its competitors. According to the industry distribution chart, Alpha Tau Medical ranks #892 out of 1412 companies in the Biotechnology industry, placing it in the top 63.2%.
Is Alpha Tau Medical's Return-on-Tangible-Asset too high?
Alpha Tau Medical's current Return-on-Tangible-Asset is -85.58%. Based on the distribution chart, Alpha Tau Medical ranks #892 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alpha Tau Medical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's Return-on-Tangible-Asset compare to ORIC and OLMA?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #892 out of 1412 companies for Return-on-Tangible-Asset. This places Alpha Tau Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Alpha Tau Medical and its competitors. Alpha Tau Medical's current Return-on-Tangible-Asset is -85.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current Return-on-Tangible-Asset of -85.58%. The current Return-on-Tangible-Asset is -85.58%. Alpha Tau Medical's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current Return-on-Tangible-Asset is -85.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
28GF Score
Get the complete analysis for DRTS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRTS has been successfully added to your 
